Cohort of IPF Patients Experiencing an Exacerbation

Sponsor
University Hospital, Gentofte, Copenhagen
Study ID
NCT04442711
Status
Recruiting
Apply to this trial

Conditions

  • Idiopathic Pulmonary Fibrosis

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Study Details

Extension of the PFBIO cohort which includes patients with newly diagnosed idiopathic pulmonary fibrosis (IPF) for longitudinal follow-up for up to 5 years. In the PFBIO-EXA extension, patients are included if they experience an exacerbation, or other increase in respiratory symptoms requiring hospital admission, for further collection of clinical and biological data.

Key Dates

First listed
Jun 22, 2020
Start date
Jun 13, 2020
Status verified
Dec 2023
Primary completion
Dec 1, 2027
Completion
Dec 31, 2028

Study Design

Enrollment
50 participants (estimated)

Arms

  • Arm: PFBIO-EXA
    All patients recruited for PFBIO-EXA from the original PFBIO cohort are included into the cohort.

Primary Outcome Measure

Mortality [ Time Frame: 30 days ]

Related Studies